Grand River Aseptic Manufacturing, the contract development and manufacturing organisation (CDMO), has announced the completion of a major expansion of its Finishing and Warehouse Centre. The expansion, which adds a substantial 90,000 square feet to the facility, is set to
Selkirk Pharma has announced the opening of a new APS Qualified Facility, marking a significant milestone in the company’s growth. The facility, located in Spokane, WA, boasts advanced fill/finish capacity, further strengthening Selkirk Pharma’s position as a CDMO (Contract Development and
Fred Turco is Vice President of Enterprise Indirects and Sustainable Sourcing Lead at Pfizer. He explains how the company is making progress towards Net Zero by collaborating with suppliers.
Almac Sciences, a member of the Almac Group, has announced a new capability to synthesise therapeutic oligonucleotides. This has been made possible by the introduction of a new RNA Ligase (RNAL) enzyme kit that extends the company’s selectAZyme™ enzyme screening
Vetter, the Ravensburg, Germany-headquartered Contract Development and Manufacturing Organisation (CDMO), has announced successful commercial launch of eight customer products in 2023. The drug products that reached the world market are used in oncology and to treat autoimmune and cardiovascular diseases,
Your guide to choose the right Cell and Gene Therapy CDMOs for your company
A bipartisan group of U.S. lawmakers has called for sanctions against Chinese biotech firm WuXi AppTec and its contract services affiliate WuXi Biologics. In a letter dated February 12, the lawmakers urged top Biden administration officials to review the global
AbbVie, a global biopharmaceutical company, announced on February 12, 2024, that it has completed its acquisition of ImmunoGen. This acquisition includes ImmunoGen’s flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx), a treatment for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC). The
What happened? Catalent, involved in producing Novo Nordisk’s top-selling GLP-1 obesity drug Wegovy, has over 50 sites globally. The acquisition follows Catalent’s strategic review due to declining revenue and issues at major manufacturing sites. The purchase price of $63.5 per
Ophthalmic APIs are small-volume products with high purity and stringent microbiology requirements. Watch the video, sponsored by C2 Pharma
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
